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Abstract Interleukin (I L)-5 is central in regulating eosinophilia 
in allergic disease and parasitic infections. We have identified a 
bipartite nuclear localisation signal (NLS) within aniino acids 
95-111 of human IL-5 (hIL-5), also present in mouse IL-5 (mlL-
5). ML-5 and mIL-5 were labelled fluorescently, and nuclear 
uptake subsequent to membrane binding and internalisation by 
intact receptor expressing cells visualised and quantified using 
confocal laser scanning microscopy. hIL-5 and mIL-5 were 
shown to be transported to the nucleus in in vivo and in vitro 
nuclear protein import assays. The hIL-5 NLS was able to target 
a heterologous protein to the nucleus both in vivo and in vitro. 
Mutations within the proximal arm of the NLS abrogated 
nuclear targeting activity, confirming its bipartite nature. The 
results imply a nuclear signalling role for IL-5 additional to 
pathways linked to the membrane receptor system. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The cytokine interleukin (IL)-5 appears to be a quite spe-
cific differentiation factor for the eosinophil cell lineage [1-6], 
recent studies with an IL-5 deficient mouse [3,4] suggesting 
that the only obligatory role of IL-5 may in fact be in con-
trolling eosinophilia. Eosinophils and IL-5 are of particular 
importance in the pathogenesis of allergic diseases [5] and 
certain parasitic infections [6]. The receptor for IL-5 consists 
of an a subunit which recognises IL-5 specifically, and a [3 
subunit which lacks ligand binding activity but which is es-
sential for signal transduction [7,8]. Interestingly, the IL-5 [3 
receptor subunit is shared with the related IL-3 and granulo-
cyte macrophage colony stimulating factor (GM-CSF) recep-
tors [7], and IL-3, IL-5 and GM-CSF exhibit overlapping 
activities on certain cell types in vitro as a direct consequence 
[7,8]. Two major signalling pathways appear to mediate IL-5's 
effects essentially through the receptor P subunit. These are 
the JAK2 (Janus kinase 2) tyrosine phosphorylation cascade 
leading to activation of STAT 1, 3 and 5 (signal transducers 
and activators of transcription 1, 3 and 5) [9-13], and the Ras-
Raf-1-MEK (mitogen-activated protein kinase (MAPK) or 
Erk kinase) microtubule-associated protein kinase pathway 
[11,14]. 
The elucidation of these two signalling pathways does not 
explain IL-5's very specific role in the differentiation and de-
velopment of eosinophils, since IL-3 and GM-CSF, which do 
not have such distinct roles, also activate the JAK2/STAT 
(e.g. [10,15]), and Ras-Raf-1-MAP kinase signalling cascades 
(see [9]). Differences in receptor expression (see [16]) also do 
not appear to explain the apparently obligatory role of IL-5 in 
controlling the eosinophil lineage. This specificity in terms of 
IL-5-signalling mechanisms additional to those emanating 
from the (3-receptor subunit shared with IL-3 and GM-CSF 
must therefore reside in particular properties of the IL-5 mol-
ecule itself or its oc-receptor subunit, whose cytoplasmic do-
main has been shown in several studies to be essential for 
signal transduction (e.g. [12,15,17]). 
We have previously noted that both human (h) and mouse 
(m) IL-5 possess sequences homologous to nuclear localisa-
tion signals (NLSs), and in particular bipartite NLSs (see [18]; 
see Table 1), which have a very distinctive structure of two 
arms of basic residues separated by a spacer of 10-12 amino 
acids [19]. This sequence is absent from both IL-3 and GM-
CSF. NLSs are the short polypeptide sequences sufficient and 
necessary to effect nuclear targeting of the proteins carrying 
them to the nucleus (see [20,21]), and have been identified in 
several polypeptide hormone ligands specific for membrane 
integral receptors and shown to have an important signalling 
role (see [18]). 
This study focuses on the nuclear targeting capacity of ba-
culovirus-expressed IL-5 in intact cells expressing the IL-5 
receptor, as well as in in vivo and in vitro nuclear transport 
assays, and the ability of its NLS to target a heterologous 
protein to the nucleus in vivo and in vitro. The results show 
that IL-5 is capable of localising in the nucleus in semi-intact 
as well as whole cells and open up the possibility of a signal-
ling role for IL-5 in the nucleus, additional to that at the 
membrane. 
*Correspondencing author. Fax: (62) (616) 2490415. 
Abbreviations: IL-5, interleukin-5; IL-3, interleukin-3; GM-CSF, 
granulocyte macrophage colony stimulating factor; JAK, Janus 
kinase; STAT, signal transducer and activator of transcription; 
NLS, nuclear localisation sequence; SFX, 6-(fluorescein-5-(and-6)-
carboxamido)hexanoic acid, succinimidyl ester; IAF, 5-iodacetamido-
fluorescein; CLSM, confocal laser scanning microscopy 
2. Materials and methods 
2.1. Chemicals and reagents 
The amino labelling reagent 6-(fluorescein-5-(and-6)-carboxamido)-
hexanoic acid, succinimidyl ester (SFX) and the sulfhydryl labelling 
reagent 5-iodacetamido-fluorescein (IAF) were from Molecular 
Probes. Other reagents were from the sources previously described 
[22-24]. 
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2.2. Cell culture 
The FDC-P1 hRa cell line is a murine factor-dependent cell line 
expressing the hIL-5 receptor a subunit which is responsive to IL-5 
owing to the presence of the mIL-5 receptor p subunit. It was derived 
from FDC-P1 cells [25] by electroporation with the hIL-5 receptor a 
subunit cDNA [26] subcloned into the expression vector pEFBOS 
[27], and selected as being hIL-5-dependent for growth. The FDC-
Pl mRcc cell line is identical to FDC-P1 hRa, except that the mlL-
5 receptor a subunit cDNA was used inserted into the expression 
vector pcDNAIneo (Invitrogen). FDC-P1 hRa and FDC-P1 mRa 
cells were cultured in RPMI Medium supplemented with 10% FCS 
and the corresponding factor. Cells of the HTC rat hepatoma tissue 
culture (a derivative of Morris hepatoma 7288C) line were cultured in 
Dulbecco's modified Eagle's medium supplemented with 10% FCS as 
described previously [23,24]. 
2.3. Baculovirus expression and purification of IL-5 
hIL-5 and mIL-5 were expressed using the baculovirus system in 
Sf9 insect cells as described previously [22]. Recombinant proteins 
were purified by gel filtration using Sephadex G-25 and then by pas-
sage through Mono Q at pH 7.4, followed by binding at pH 9.2, and 
subsequent elution using a 0-350 mM NaCl gradient. 
2.4. $-Galactosidase fusion proteins 
Plasmids expressing the wild type hIL-5-NLS P-galactosidase fusion 
proteins were derived by oligonucleotide insertion into the Smal re-
striction endonuclease site of the plasmid vector pPR2 [28]. The re-
sultant fusion protein contains hIL-5 amino acids 93-112 (see Table 1) 
fused N-terminal to the Escherichia coli P-galactosidase enzyme se-
quence (amino acids 9-1023). The plasmid expressing the hIL-5-
NLSmut P-galactosidase fusion protein (see Table 1) was derived by 
oligonucleotide site-directed mutagenesis of the hIL-5-NLS P-galacto-
sidase fusion protein expressing construct using the Clontech Trans-
former Kit, as described previously [24]. 
1 mM isopropyl-p-thiogalactoside was used to induce expression of 
P-galactosidase fusion proteins in E. coli. They were purified by affin-
ity chromatography as described previously [24,28]. 
2.5. Fluorescent labelling 
IL-5 was labelled using the covalent amine-labelling reagent SFX, 
whereby 100 ug of freshly prepared SFX (5 mg/ml in DMSO) was 
added to 200 |xg of protein (in phosphate-buffered saline (PBS)) and 
incubated at room temperature for 1.5 h (in the dark). PBS was then 
added to bring the sample volume to 500 ul, and the total volume 
loaded on to a NAP-5 column (Pharmacia) to separate the labelled 
protein from free dye. The sample was eluted with 1 ml of PBS, and 
protein samples concentrated using 'Ultrafree-MC filter units (Milli-
pore). Labelled hIL-5 retained greater than 50% biological activity 
(1.23X106 ED50 U/ml) compared to unlabelled material as assessed 
in thymidine incorporation assays [29], whilst labelled mIL-5 also 
retained biological activity (1.1 XlO5 ED50 U/ml). 
P-Galactosidase fusion proteins were labelled with IAF as described 
previously [24,28], 
2.6. Nuclear transport assays 
In vivo and in vitro nuclear import kinetics at the single cell level, 
using microinjected or mechanically perforated HTC cells respectively, 
in conjunction with confocal laser scanning microscopy (CLSM), was 
as described previously in detail [23,24,30]. In the case of in vivo 
assays, HTC cells were fused with polyethylene glycol (PEG) about 
1 h prior to microinjection to produce polykaryons and injected using 
a Narshige IM-200 pneumatic microinjector and Leitz micromanipu-
lator [24]. The in vitro assay was carried out in the presence of 45 mg/ 
ml cytosolic extract (untreated reticulocyte lysate; Promega Cat. No. 
L415A) and an ATP regenerating system [24,30]. Image analysis of 
CLSM files, and curve fitting to the equation Fn/c (t) = Fn/ 
Cmax*(l— e_kt) was performed as described [23,24,28,30]. Fn/cmax is 
the maximal level of nuclear accumulation whilst the first order rate 
constant (k) is the rate at which Fn/cmax is reached. 
expressed hIL-5 and mIL-5 were fluoresceinated with SFX 
to yield fluorescent derivatives. The derivatives retained bio-
logical activity in proliferation assays with mouse FDC PI 
cells expressing the cDNAs for the hIL-5 (FDC PI hRa cells) 
or mIL-5 (FDC PI mRa cells) a-receptor subunits respec-
tively in addition to the endogenous IL-5 P-receptor subunit. 
Both derivatives were found to be able to bind specifically to 
and be internalised by the appropriate FDC PI cells as visual-
ised by CLSM. A 10-fold excess of unlabelled IL-5 could 
compete for binding (see Fig. 1A, compare left and right 
panels for total and non-specific binding respectively), dem-
onstrating that the process was receptor-mediated. Fig. IB 
comprises the quantitative data for membrane and nuclear 
fluorescence due to specific (values for non-specific binding 
subtracted) binding and uptake of ML-5-SFX by FDC PI 
hRa cells. Membrane binding was rapid (maximal at about 
10 min), with membrane-bound ligand diminishing with time 
thereafter at 37°C due to internalisation (Fig. IB). A second 
'peak' of membrane binding activity appeared to be present 22 
h after ligand addition, presumably the result of receptor re-
cycling and appearance of new receptors on the membrane 
surface. Specific nuclear fluorescence was detectable as soon 
as 45 min after ligand addition at 37°C, reaching maximal 
levels at around 5-6 h (see Fig. IB, and data not shown), at 
which time nuclear concentrations were higher than those at 
the membrane. As expected, specific nuclear (as opposed to 
membrane) fluorescence was not measurable even up to 4h 
incubation at 4°C (Fig. IB, and not shown), implying that 
nuclear localisation occurs subsequent to receptor internalisa-
tion, which is inhibited at 4°C [31,32]. 
3.2. Nuclear accumulation of hIL-5 and mIL-5 in vivo and 
in vitro 
The results from the whole cell experiments indicated that 
subsequent to binding and internalisation, IL-5 is able to 
make its way to the nucleus. In order to confirm that IL-5 
possesses nuclear targeting activity, the nuclear import ki-
netics of hIL-5-SFX and mIL-5-SFX were measured in estab-
Table 1 
Bipartite NLSs in human and mouse IL-5 compared to those in 
SWI5, N1N2 and nucleoplasmin, and hIL-5 sequences in the ML-5-
NLS-P-galactosidase fusion proteins used in this study 
P r o t e i n 
SWI5 
N1N2 
n u c l e o p l a s m i n 
CONSENSUS 
mouse I L - 5 
human I L - 5 
B i p a r t i t e NLS+ 
I — 1 0 a a — I 
KKYENWIKRSPRKRGRPRK655 [ 2 3] 
RKKRKTEEESPLKDKAKKSK554 [19] 
KRPAATKKAGQAKKKKLDK174 [19] 
K K - 1 0 - 1 2 aa-KKK 
RR RRR 
I 12 a a 1 
LIKKYIDRQKEKCGEERRRTRQ113 
LIKKYIDGQKKKCGEERRRVNQ114 
B) hIL-5 sequences i n hIL-5-NLS-[j-aalact :osidase fus ion p r o t e i n 
I L - 5 - N L S - P - g a l LIKKYIDGQKKKCGEERRRV 
I L - 5 - N L S m u t - | 3 - g a l L I ttYIDGQKKKCGEERRRV 
3. Results 
3.1. Nuclear localisation of IL-5 in receptor expressing cells 
To carry out subcellular localisation studies, baculovirus 
+The single letter amino acid code is used, and the proximal and 
distal arms of basic residues of the bipartite NLS are in bold. 
References for confirmed NLSs are indicated (see also [19,21]). aa, 
amino acids. 
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Fig. 1. Binding and uptake of human interleukin-5 by FDC-Pl hRa cells. A: Visualisation of the membrane binding of hIL-5 to FDC-Pl hRa 
cells. Cells were washed 4 times in factor-free RPMI and then incubated for 60 min at 37°C with 975 nM hIL-5-SFX in the absence and pres-
ence of a 10-fold excess of unlabelled hIL-5, prior to mounting and visualisation of fluorescence using CLSM. B: Specific membrane and nu-
clear fluorescence due to membrane binding and internalisation of fluorescently labelled hIL-5 by FDC-Pl hRa cells. Cells were treated as in 
A, prior to mounting and examination using CLSM. Image analysis was performed to quantitate membrane and nuclear fluorescence in the ab-
sence (fluorescence due to total binding) and presence (fluorescence due to non-specific binding) of unlabelled hIL-5, with the latter subtracted 
from the former to give a measure of the fluorescence ('specific fluorescence') due to specific binding. Incubations were all carried out at 37°C, 
except that of 180 min at 4°C (right-most column). Results represent at least 28 measurements for each of the fluorescent measurements of to-
tal and non-specific binding, with the S.E.M. less than 3.2% the value of the mean. 
lished in vivo (microinjected HTC rat hepatoma cells) 
[23,24,28] and in vitro (mechanically perforated HTC cells 
[24,30]) nuclear transport assay systems using CLSM. Both 
ligands accumulated rapidly in the nucleus both in vivo 
(Fig. 2A, top panels and Fig. 2B, panel A) and in vitro 
(Fig. 3) to levels over 2-fold those in the cytoplasm, steady 
state being achieved within 1-3 min. 
3.3. The hIL-5 NLS can target a heterologous protein to the 
nucleus 
We had previously identified putative bipartite NLSs in the 
sequences of both hIL-5 (amino acids 95-111) and mIL-5 
(amino acids 94-110) [18] (see Table 1). To test whether these 
sequences might play a role in the nuclear targeting of IL-5 
observed in intact cells, as well as in in vivo and in vitro 
nuclear transport systems, (3-galactosidase fusion protein ex-
pressing plasmid constructs were derived containing either the 
wild type hIL-5-NLS, or a mutant version in which lysines 95 
and 96 were substituted by threonine residues (see Table 1), 
thus neutralising the proximal arm of the bipartite NLS; sim-
ilar mutations abolish the nuclear targeting activity of other 
bipartite NLSs such as those listed in Table 1. Nuclear import 
of the hIL-5-NLS fusion protein derivatives was examined 
both in vivo (Fig. 2) and in vitro (Fig. 3), the hIL-5 NLS 
being capable of targeting the heterologous E. coli protein 
p-galactosidase (476 kDa) to the nucleus in both assay sys-
tems. The maximal levels of hIL-5-NLS-p-Gal nuclear accu-
mulation in vitro were comparable to those of hIL-5-SFX 
(Fig. 3B), although the rate of accumulation was slower, con-
sistent with the larger size of the fusion protein compared to 
IL-5. These results were similar to those for a P-galactosidase 
fusion protein containing the SWI5 bipartite NLS [23]. 
Although not as rapid as that of hIL-5-SFX, nuclear accumu-
lation of hIL-5-NLS-p-Gal in microinjected cells could be 
readily visualised (Fig. 2A, bottom left panel) and quantified 
(Fn/c of 1.3 about 90 min after injection; Fig. 2B). The hIL-5-
NLSmut-[5-Gal protein was completely excluded from the nu-
cleus both in vivo and in vitro (Fn/cmax of about 0.5, indica-
tive of exclusion from the nucleus; Fig. 2FIg. 3) even up to 
150 min in vivo (not shown), confirming the bipartite nature 
of the NLS. Although its significance is unclear at this stage, 
an intriguing observation was the fact that at later time points 
in vitro, hIL-5-NLSmut-P-Gal appeared to preferentially lo-
calise around the periphery of the nucleolus (Fig. 3A). Similar 
although not so pronounced localisation around the nucleolar 
periphery was evident for hIL-5 and mIL-5 (Fig. 3A). 
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Fig. 2. Nuclear uptake of hIL-5, mIL-5 and hIL-5-p-galactosidase fusion protein derivatives in vivo. A: Visualisation of nuclear uptake in mi-
cromjected HTC cells. HTC cells were fused with PEG 1 h prior to micromjection, performed as described in Section 2. CLSM images are 
shown for cells 6-9 min (hIL-5 and mIL-5; upper panels) or 35^ M) min (p-galactosidase fusion proteins; lower panels) after microinjection at 
37°C. B: Nuclear transport kinetics of hIL-5 and mIL-5 (A) and hIL-5-(3-galactosidase fusion protein derivatives (B) in microinjected HTC cells 
as measured by quantitative CLSM. Measurements, performed as described in Section 2 [23,24,28], represent the average of at least two sepa-
rate experiments, where each point represents the average of 6-10 separate measurements for each of nuclear (Fn) and cytoplasmic (Fc) fluores-
cence respectively, with autofluorescence subtracted. 
4. Discussion 
A number of recent studies have encouraged reassessment 
of the traditional concept of hormonal action being confined 
to signal transduction events at the level of the membrane, 
indicating that polypeptide hormones such as prolactin, plate-
let-derived growth factor (PDGF), fibroblast growth factor 
(FGF), growth hormone (GH) and insulin have significant 
nuclear signalling roles (see [18]). Molecules of the PDGF 
and acidic FGF (aFGF) classes have in fact been demon-
strated to possess functional NLSs [33,34], which in the case 
of PDGF A and aFGF appear to be necessary for full mito-
genic activity ([35,36]; see [18]). Our results here show that IL-
5, in similar fashion to these growth factors, possesses a func-
tional NLS capable of targeting a large (476 kDa) heterolo-
gous protein to the nucleus both in vivo and in vitro. The 
bipartite NLS we have defined for hIL-5 is presumably the 
sequence element responsible for targeting IL-5 to the nucleus 
in in vivo and in vitro nuclear transport assays, and in intact 
receptor expressing cells. 
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Fig. 3. Nuclear uptake of hIL-5, mIL-5 and hIL-5-p-galactosidase fusion protein derivatives in vitro. A: Visualisation of nuclear uptake in me-
chanically perforated HTC cells. Results are shown at the time points indicated in the presence of exogenously added cytosol and an ATP-re-
generating system at room temperature. Nucleolar rim staining (indicated by the arrows) at later time points is shown in the right panels. B: 
Nuclear import kinetics of hIL-5 and mIL-5 (A) and hIL-5-P-galactosidase fusion protein derivatives (B) in mechanically perforated HTC cells 
as measured by quantitative CLSM. Measurements, performed as described in Section 2 [24,30], represent the average of at least 2 separate ex-
periments, where each point represents the average of 5-8 separate measurements for each of Fn and Fc respectively, with autofluorescence 
subtracted. 
This study shows that, in analogous fashion to ligands such 
as FGF, GH, interferon-y [37], IL-loc [38], etc. (see [18]), IL-5 
is capable of localising in the nucleus subsequent to binding to 
its specific receptor at the membrane and endocytosis. The 
amount of internalised ligand that ultimately makes its way 
to the nucleus (perhaps 20-25% of the total ligand originally 
bound) is likely to be significant in terms of signalling. The 
role of IL-5 in the nucleus may take the form either of influ-
encing transcription directly by binding to chromatin in anal-
ogous fashion to basic FGF or GH ([39,40]; see also [18]), or 
through cotargeting bound receptor subunits and possibly 
other signalling molecules (e.g. JAKs) to the nucleus where 
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they may modulate the activity of nuclear transcription fac-
tors (see [18,41]). Nuclear targeting of IL-5 may conceivably 
be the basis of IL-5's highly specific signal transduction role 
with respect to regulation of the eosinophil lineage and re-
cruitment of eosinophils to the sites of inflammation [3-6], 
additional to the signalling functions it shares with IL-3 and 
G M - C S F through the common (3-receptor subunit. 
In summary, our observations raise the intriguing possibil-
ity that the IL-5 N L S may be the basis of its unique signalling 
properties with respect to eosinophil differentiation etc., dis-
tinct from those of the related IL-3 and G M - C S F molecules. 
Future work in this laboratory will enlarge upon the obser-
vations reported in this study in trying to determine the 
unique signalling role of IL-5, with or without its specific 
receptor subunits, in the nucleus. 
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